🇺🇸

US SEC Filing Intelligence

· daily

Contract Option Exercises — October 04, 2026

The three contract option exercises from October 4, 2026, total $1.76 billion in obligations, with zero defense-related awards, signaling a purely civilian-agency procurement theme. The dominant agency is the General Services Administration (GSA) via a $694M Leidos geospatial engineering contract, though its expired performance period and negative outlay raise material execution concerns. The highest-conviction signal is the $571M PAE/Amentum DHS aircraft maintenance award, which aligns with stable border security funding but shows minimal outlay to date. Key risks include the Leidos contract's negative outlay suggesting potential cancellation, and the TOTE Services $15M award being a one-time event with no recurring revenue visibility. Investors should watch for re-compete announcements or modifications on these contracts to validate revenue recognition and pipeline strength.

3 total filings
· daily

Federal Professional Services Contracts — October 04, 2026

This single-day digest covers one large, expired civilian contract from the General Services Administration (GSA) to Leidos, Inc. valued at $694M obligated ($788M with options). The contract is entirely civilian, not defense-related, and carries a neutral signal with low materiality due to its November 2021 completion and a negative outlayed amount (-$163K), suggesting possible underperformance or cancellation. The dominant theme is geospatial engineering services for civilian agencies, but the lack of current revenue impact limits actionable investment insight. The key risk is the negative outlay, which may indicate contract termination or underfunding, requiring monitoring for future GSA geospatial awards to assess pipeline strength.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — October 04, 2026

The October 4, 2026 mega-contract stream totals $1.76 billion across three civilian awards, with zero defense-related contracts, highlighting a continued focus on non-DOD federal spending. The dominant theme is infrastructure and services modernization, led by a $694 million GSA award to Leidos for geospatial engineering (though expired with negative outlay), a $571 million DHS/CBP aircraft maintenance contract to PAE/Amentum (largely un-outlayed), and a $497 million DOT/Maritime Administration shipbuilding slot reservation to TOTE Services. The highest-conviction signal is the DHS/CBP award to Amentum, given its alignment with stable border security funding and the company's competitive win, but execution risk is elevated due to minimal outlays across all contracts. Key watch items include the negative outlay on Leidos' contract and the short performance windows, which suggest potential revenue recognition issues or cancellations.

3 total filings
· daily

High-Value Federal Grants ($5M+) — October 04, 2026

This digest covers three high-value federal grants totaling $1.76 billion, all awarded to civilian agencies (GSA, DHS, DOT) with zero defense-related content. The dominant theme is large, expired or underfunded contracts for engineering and maintenance services, with Leidos' $694M GSA geospatial contract and PAE/Amentum's $572M DHS aircraft maintenance contract both showing negative or minimal outlays—raising serious execution or cancellation concerns. The highest-conviction signal is the negative outlay on Leidos' award, which suggests potential contract termination or underperformance, while TOTE Services' $15M DOT shipbuilding contract is a one-time event with no recurring revenue. Key risk: the aggregate data reveals that two of the three contracts (Leidos and PAE) have expired performance periods and negligible actual spending, indicating that headline obligation values may not translate to realized revenue for investors.

3 total filings
· daily

General Federal Contracts — October 04, 2026

The three contracts analyzed total $1.76 billion in obligations, all from civilian agencies (GSA, DHS/CBP, DOT/MARAD), with zero defense-related awards. The dominant theme is legacy infrastructure and support services—geospatial engineering (Leidos), aircraft maintenance (PAE/Amentum), and shipbuilding (TOTE Services)—rather than cutting-edge technology. The highest-conviction signal is the Leidos $694M GSA award, which, despite its size, carries a bearish negative outlay (-$163K) and an expired performance period, indicating potential cancellation or underperformance. A key risk is the PAE $572M DHS contract, where only $2.1M of $572M has been outlayed, suggesting severe execution or budget delays. Overall, these contracts point to stable but low-growth civilian spending, with no clear bullish catalyst for public equities.

3 total filings
· daily

Defense Manufacturing Contracts — October 03, 2026

This digest covers a single $254.3 million firm-fixed-price delivery order awarded to The Boeing Company by NASA under the Commercial Crew Program, with a total potential value of $363.6 million including options through May 2027. The contract is entirely civilian (0/1 defense-related) and reflects NASA's sustained commitment to human spaceflight. The highest-conviction signal is the neutral risk/reward profile: predictable revenue from a fixed-price structure is offset by execution risk over an 11.5-year performance period. A key risk is potential cost overruns or delays on the fixed-price contract, which could impact Boeing's quarterly earnings.

1 total filings
· daily

New Federal Contractors — October 03, 2026

The two contracts analyzed total $541.7 million in obligations, both awarded to civilian agencies (NASA and GSA) with zero defense-related content, reflecting a pure civilian-sector procurement theme. The highest-conviction signal is Boeing’s $254.3 million firm-fixed-price delivery order under NASA’s Commercial Crew Program, which offers predictable long-term revenue through May 2027 but carries execution risk from fixed-price exposure. SAIC’s $287.5 million cost-plus-fixed-fee GSA engineering services contract is historical (ended Dec 2022) and shows complex financial flows with $665 million in subawards, signaling potential margin compression. Key risk: SAIC’s contract is no longer contributing to current revenue, and its high subaward ratio warrants scrutiny of margin retention. The aggregate signal strength is neutral (5.5/10), with no bullish or bearish signals identified, underscoring a balanced but cautious investment view for these legacy awards.

2 total filings
· daily

Significant Contract Modifications ($10M+) — October 03, 2026

This digest covers two significant contract modifications totaling $541.7 million, both awarded to civilian agencies (GSA and NASA) with zero defense-related content, signaling a pure civilian-sector investment story. The dominant theme is long-duration, high-value space and engineering services contracts, with The Boeing Company ($254.3M) and Science Applications International Corporation (SAIC) ($287.5M) as the sole recipients. The highest-conviction signal is Boeing's firm-fixed-price NASA Commercial Crew contract, which offers predictable revenue through May 2027 but carries medium execution risk due to fixed-price exposure. A key risk is that both contracts are historical or nearing completion (SAIC's ended Dec 2022, Boeing's runs through May 2027), meaning current revenue contributions may be overstated without evidence of extensions or new awards.

2 total filings
· daily

Contract Deobligations Alert — October 03, 2026

This digest covers two large, non-defense contracts totaling $541.7 million, both awarded to legacy prime contractors—SAIC ($287.4M) and Boeing ($254.3M)—by civilian agencies (GSA and NASA). The dominant theme is long-duration, fixed-price or cost-plus engineering and space transportation services, with Boeing’s NASA Commercial Crew contract offering the highest-conviction signal due to its firm-fixed-price structure and 11.5-year performance period through 2027. However, both contracts are historical awards (2015-2017) with no current defense exposure, limiting near-term catalyst potential. Key risks include SAIC’s compressed margins from a $665M subaward flow-through and Boeing’s fixed-price execution risk on a multi-year space program.

2 total filings
· daily

Contract Option Exercises — October 03, 2026

This digest covers two contract option exercises totaling $541.7 million, both civilian (NASA and GSA), with no defense-related awards. The dominant theme is sustained civilian agency investment in engineering and space transportation services, with SAIC ($287.4M cost-plus-fixed-fee) and Boeing ($254.3M firm-fixed-price) representing contrasting risk profiles. The highest-conviction signal is Boeing's long-duration NASA Commercial Crew Program commitment through 2027, offering predictable revenue but fixed-price execution risk. A key watch item is SAIC's high subaward ratio ($665M vs. $287.5M obligated), which may compress margins and warrants scrutiny of subcontractor dependencies.

2 total filings
· daily

Federal Professional Services Contracts — October 03, 2026

This digest covers a single, large civilian contract awarded to Science Applications International Corporation (SAIC) by the General Services Administration (GSA) for engineering services, valued at $287.4 million. The contract is entirely civilian (0% defense-related), cost-plus-fixed-fee in structure, and historical in nature, having ended in December 2022. The highest-conviction signal is neutral, reflecting the contract's low profit-risk profile but offset by a massive $665 million subaward total that suggests compressed margins and complex financial flows. Key risks include the contract's age (no current revenue contribution unless extended) and the potential for SAIC to be acting as a pass-through entity, limiting earnings quality. Investors should monitor for any follow-on awards under the same GSA vehicle and SAIC's broader reliance on cost-plus contracting.

1 total filings
· daily

NASA & Space Contracts Intelligence — October 03, 2026

This digest covers a single, large civilian NASA contract awarded to The Boeing Company valued at $254.3 million (with a potential $363.6 million including options), representing 100% of the period's total obligation. The contract, a firm-fixed-price delivery order under NASA's Commercial Crew Program, supports the design and certification of an integrated crew transportation system for ISS missions through May 2027. The highest-conviction signal is neutral, reflecting Boeing's entrenched competitive position in human spaceflight but tempered by fixed-price execution risk and a long performance period. A key risk is the potential for cost overruns on this fixed-price structure, which has historically challenged Boeing in similar NASA programs.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — October 03, 2026

This digest covers two mega contracts totaling $541.7 million, both awarded to civilian agencies (GSA and NASA) with zero defense-related obligations, signaling a non-DoD procurement focus for the period. The dominant theme is long-duration, high-value engineering and space transportation services, with SAIC ($287.4M) and Boeing ($254.3M) as the sole recipients. The highest-conviction signal is Boeing’s fixed-price NASA Commercial Crew contract, which provides predictable revenue through 2027 but carries medium execution risk due to fixed-price exposure. A key risk is SAIC’s historical cost-plus contract, which ended in 2022 and shows negative outlayed amounts, suggesting complex financial flows and no current revenue contribution. Investors should watch for any extensions or new awards under SAIC’s vehicle and monitor Boeing’s option exercises for post-certification missions.

2 total filings
· daily

High-Value Federal Grants ($5M+) — October 03, 2026

This digest covers two high-value federal grants totaling $541.7 million, both awarded to major defense contractors (SAIC and Boeing) but entirely under civilian agencies (GSA and NASA), reflecting zero defense exposure. The dominant theme is long-duration, high-certainty civilian space and engineering services programs, with Boeing’s $254.3 million NASA Commercial Crew contract (2015-2027) offering the highest-conviction signal of sustained revenue visibility despite fixed-price execution risk. The highest-conviction signal is Boeing’s firm-fixed-price structure, which provides predictable revenue but carries medium execution risk from potential cost overruns on crew transportation development. Key risk: SAIC’s $287.5 million GSA contract is historical (ended 2022), offering no current revenue contribution, and its high subaward ratio ($665M subawards vs. $287.5M obligation) signals compressed margins and complex financial flows that warrant caution on future similar awards.

2 total filings
· daily

General Federal Contracts — October 03, 2026

This digest covers two civilian agency contracts totaling $541.7 million, with no defense-related awards, highlighting a pure civilian-sector theme centered on NASA and GSA. The highest-conviction signal is Boeing’s $254.3 million firm-fixed-price NASA Commercial Crew contract (2015–2027), which offers long-term revenue visibility but carries medium execution risk due to fixed-price exposure. The SAIC $287.4 million GSA engineering services contract is historical (ended 2022), providing no current revenue contribution and flagged for complex financial flows. Key risks include Boeing’s fixed-price execution risk on a multi-year space program and SAIC’s compressed margins from high subaward pass-throughs. Investors should monitor NASA option exercises for Boeing and any GSA re-compete opportunities for SAIC.

2 total filings
· daily

All NASA Contracts — October 03, 2026

This digest covers a single NASA contract award to The Boeing Company valued at $254.3 million obligated, with a total potential value of $363.6 million including options, under NASA's Commercial Crew Program. The contract is entirely civilian, with no defense-related obligations, and spans from December 2015 to May 2027, reflecting long-term program stability. The highest-conviction signal is neutral, given the fixed-price structure and full-and-open competition, which provide revenue visibility but also execution risk. Key watch items include Boeing's ability to manage fixed-price risk and NASA's option exercise decisions for post-certification missions.

1 total filings
· daily

Biotech Small-Cap Approvals — October 02, 2026

The October 2, 2026 approval stream for biotech small-caps delivered 13 approvals, all classified as 'Other' with no NME, biosimilar, or label expansion designations per the provided data. The mix is heavily weighted toward neutral biosimilar-type approvals (7 neutral) and 6 bullish signals, with the highest-conviction events being three NME approvals: TIRATRICO (EMCITATE) from RARE THYROID THERAPEUTICS INTERNATIONAL AB, DENOSUMAB-ADET (DEGEVMA) from TEVA PHARMACEUTICALS, and ZILURGISERTIB (ATEBRIOZ) from INCYTE CORP, all carrying Priority Review and Orphan designations (except DENOSUMAB-ADET which lacks explicit designations). The dominant therapeutic theme is specialty/rare disease, with oncology and metabolic signals from INCYTE and TEVA, plus a rare thyroid entry. The highest-conviction signal is INCYTE's ZILURGISERTIB, an NME with Priority Review and Orphan status, indicating strong commercial potential in a niche oncology indication. Key risks include the lack of detailed commercial data (peak sales, exclusivity, pricing) across all approvals, and the potential for IRA negotiation exposure on small-molecule NMEs like ZILURGISERTIB and TIRATRICO, though timelines are not specified.

13 total filings
· daily

NME Blockbuster Approvals — October 02, 2026

During the period of October 2, 2026, the FDA approved two NMEs under Priority Review and Orphan Drug designations, signaling a bullish day for rare disease-focused sponsors. TIRATRICO (EMCITATE) from RARE THYROID THERAPEUTICS INTERNATIONAL AB and ZILURGISERTIB (ATEBRIOZ) from INCYTE CORP both received approvals, though neither was classified as a standard NME in the stream mix. The dominant therapeutic theme is rare disease specialization, with both drugs targeting narrow, high-unmet-need populations. The highest-conviction signal is INCYTE CORP’s approval of ZILURGISERTIB, reinforcing its oncology/hematology pipeline execution. Key risk: both approvals lack disclosed peak sales estimates and pricing details, creating commercial uncertainty despite strong regulatory signals.

2 total filings
· daily

Big Pharma Approvals — October 02, 2026

This period's FDA digest is dominated by a single, high-conviction NME approval for ABBVIE INC's TAVAPADON (JUVMO), a 'FALLBACK' type approval that signals a strategic pivot or new pipeline entry for the sponsor. With zero biosimilar or label expansion activity, the investment story is narrowly focused on ABBVIE's ability to commercialize a new molecular entity. The bullish signal (8/10 strength, 8/10 materiality) suggests significant commercial potential, though the lack of disclosed peak sales, exclusivity, or pricing data introduces uncertainty. The key risk is the opaque 'FALLBACK' designation, which may imply a contingency approval or a drug with a limited indication, requiring close monitoring of launch execution and payer reception.

1 total filings
· daily

Orphan Drug Approvals — October 02, 2026

The October 2, 2026 orphan drug approval digest features 3 approvals, all designated as 'Other' (non-NME, non-biosimilar, non-label expansion) but functionally representing 2 high-value New Molecular Entity (NME) approvals and 1 label expansion. The dominant therapeutic area is rare disease, with two NMEs—TIRATRICO (EMCITATE) from Rare Thyroid Therapeutics International AB and ZILURGISERTIB (ATEBRIOZ) from Incyte Corp—both receiving Priority Review and Orphan Drug designations, signaling strong unmet need and premium pricing potential. The highest-conviction signal is the dual NME approvals for Rare Thyroid Therapeutics and Incyte, each carrying 8/10 bullish signals and materiality, suggesting significant commercial opportunities in niche orphan markets. A key risk is the lack of disclosed peak sales estimates and exclusivity details, making precise revenue modeling impossible, while the label expansion for MAVACAMTEN (CAMZYOS) from Bristol-Myers Squibb provides incremental but lower-conviction upside.

3 total filings